Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Glanzmann's Thrombasthenia: A Prospective Observational Registry

Next Previous
Trial Profile

Treatment of Glanzmann's Thrombasthenia: A Prospective Observational Registry

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eptacog alfa (Primary)
  • Indications Thrombasthenia
  • Focus Therapeutic Use
  • Acronyms GTR
  • Sponsors Novo Nordisk

Most Recent Events

  • 29 Oct 2020 Results of analysis assessing efficacy and safety of rFVIIa using data from Glanzmann's Thrombasthenia Registry (n=133), Novo Nordisk safety surveillance database and published literature (1 Jan 1999 to 1 Dec 2017) published in the Thrombosis and Haemostasis
  • 07 Jul 2014 According to a Novo Nordisk media release, eptacog alfa (NovoSeven RT) was approved by the US FDA for the perioperative management and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
  • 13 May 2014 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top